412 related articles for article (PubMed ID: 23471131)
1. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.
Isakova T; Barchi-Chung A; Enfield G; Smith K; Vargas G; Houston J; Xie H; Wahl P; Schiavenato E; Dosch A; Gutiérrez OM; Diego J; Lenz O; Contreras G; Mendez A; Weiner RB; Wolf M
Clin J Am Soc Nephrol; 2013 Jun; 8(6):1009-18. PubMed ID: 23471131
[TBL] [Abstract][Full Text] [Related]
2. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Ix JH; Isakova T; Larive B; Raphael KL; Raj DS; Cheung AK; Sprague SM; Fried LF; Gassman JJ; Middleton JP; Flessner MF; Block GA; Wolf M
J Am Soc Nephrol; 2019 Jun; 30(6):1096-1108. PubMed ID: 31085679
[TBL] [Abstract][Full Text] [Related]
3. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.
Chang YM; Tsai SC; Shiao CC; Liou HH; Yang CL; Tung NY; Hsu KS; Chen IL; Liu MC; Kao JL; Jhen RN; Huang YT
Clin Exp Nephrol; 2017 Oct; 21(5):908-916. PubMed ID: 27928636
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.
Isakova T; Gutiérrez OM; Smith K; Epstein M; Keating LK; Jüppner H; Wolf M
Nephrol Dial Transplant; 2011 Feb; 26(2):584-91. PubMed ID: 20631407
[TBL] [Abstract][Full Text] [Related]
5. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients.
Soriano S; Ojeda R; Rodríguez M; Almadén Y; Rodríguez M; Martín-Malo A; Aljama P
Clin Nephrol; 2013 Jul; 80(1):17-22. PubMed ID: 23391319
[TBL] [Abstract][Full Text] [Related]
6. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.
Ureña-Torres P; Prié D; Keddad K; Preston P; Wilde P; Wan H; Copley JB
BMC Nephrol; 2014 May; 15():71. PubMed ID: 24885942
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
[TBL] [Abstract][Full Text] [Related]
8. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
Spatz C; Roe K; Lehman E; Verma N
Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
[TBL] [Abstract][Full Text] [Related]
9. Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease.
Goto S; Nakai K; Kono K; Yonekura Y; Ito J; Fujii H; Nishi S
Clin Exp Nephrol; 2014 Dec; 18(6):925-31. PubMed ID: 24578219
[TBL] [Abstract][Full Text] [Related]
10. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
Liabeuf S; Ryckelynck JP; El Esper N; Ureña P; Combe C; Dussol B; Fouque D; Vanhille P; Frimat L; Thervet E; Mentaverri R; Prié D; Choukroun G;
Clin J Am Soc Nephrol; 2017 Dec; 12(12):1930-1940. PubMed ID: 29074818
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
[TBL] [Abstract][Full Text] [Related]
12. Effects of phosphate binders in moderate CKD.
Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
[TBL] [Abstract][Full Text] [Related]
13. Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT).
Adema AY; de Jong MA; de Borst MH; Ter Wee PM; Vervloet MG;
Nephron; 2016; 134(4):215-220. PubMed ID: 27442253
[TBL] [Abstract][Full Text] [Related]
14. Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study.
Ix JH; Anderson CA; Smits G; Persky MS; Block GA
Am J Clin Nutr; 2014 Nov; 100(5):1392-7. PubMed ID: 25332338
[TBL] [Abstract][Full Text] [Related]
15. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
16. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
17. Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
Adema AY; de Borst MH; Ter Wee PM; Vervloet MG;
J Ren Nutr; 2014 May; 24(3):143-50. PubMed ID: 24216259
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M
Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
[TBL] [Abstract][Full Text] [Related]
19. Phosphate control in reducing FGF23 levels in hemodialysis patients.
Rodelo-Haad C; Rodríguez-Ortiz ME; Martin-Malo A; Pendon-Ruiz de Mier MV; Agüera ML; Muñoz-Castañeda JR; Soriano S; Caravaca F; Alvarez-Lara MA; Felsenfeld A; Aljama P; Rodriguez M
PLoS One; 2018; 13(8):e0201537. PubMed ID: 30086150
[TBL] [Abstract][Full Text] [Related]
20. Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Zhao SJ; Wang ZX; Chen L; Wang FX; Kong LD
Ann Palliat Med; 2022 Apr; 11(4):1264-1277. PubMed ID: 34775773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
